TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28347975

Group type: EXPERIMENTAL
Intervention: Daily text message reminders for a 30‐day intervention phase following hospitalization.
Number of subjects: 40
Study: 26182956

Group type: EXPERIMENTAL
Intervention: Whole-school restorative approach to address bullying and aggression
Number of subjects: 1144

Group type: COMPARATOR
Intervention: Standard practice
Number of subjects: 1144
Study: 24138537

Group type: COMPARATOR
Intervention: LPV/r 400/100 mg
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: LPV/r 600/150 mg
Number of subjects: 63
Study: 21290136

Group type: EXPERIMENTAL
Intervention: Laparoscopic inguinal herniotomy
Number of subjects: 2699
Study: 19496959

Group type: EXPERIMENTAL
Intervention: Venlafaxine 150-225 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 16455387

Group type: EXPERIMENTAL
Intervention: Patients with allergic rhinitis
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 26
Study: 14669181

Group type: EXPERIMENTAL
Intervention: Treadmill training with partial body-weight support (TT-BWS)
Number of subjects: 80
Study: 11269898

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control (drugs only)
Number of subjects: 19
Study: 8985765

Group type: EXPERIMENTAL
Intervention: Mupirocin nasal ointment
Number of subjects: 226

Group type: COMPARATOR
Intervention: Control group (historic control)
Number of subjects: 226
Study: 1456861

Group type: EXPERIMENTAL
Intervention: PCEP lecture + generic chart reminders of NCEP guidelines
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: PCEP lecture + timely patient-specific feedback
Number of subjects: 240

Group type: COMPARATOR
Intervention: PCEP lecture only (Control group)
Number of subjects: 240
Study: 3969035

Group type: EXPERIMENTAL
Intervention: Smoking intervention programme administered by general practitioners
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study: 30473185

Group type: EXPERIMENTAL
Intervention: ETVAX with dmLT adjuvant
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: ETVAX without dmLT adjuvant
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 30879831

Group type: EXPERIMENTAL
Intervention: XEN® Gel Stent as a stand-alone procedure
Number of subjects: 777

Group type: EXPERIMENTAL
Intervention: XEN® Gel Stent in combined surgery
Number of subjects: 777

Group type: COMPARATOR
Intervention: Complications
Number of subjects: 777
Study: 28406791

Group type: EXPERIMENTAL
Intervention: Patient-centered assessment process
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Engagement of patient and physician stakeholders
Number of subjects: 0
Study: 25933728

Group type: EXPERIMENTAL
Intervention: Liberal RBC transfusion strategy (Hb < 11.3 g/dL, 7 mmol/L)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Restrictive RBC transfusion strategy (Hb < 9.7 g/dL, 6 mmol/L)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Both strategies
Number of subjects: 157
Study: 23903529

Group type: EXPERIMENTAL
Intervention: Bovine colostrum protein concentrate (CPC) supplementation (10 g/day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (10 g whey protein concentrate/day)
Number of subjects: 10
Study: 22077684

Group type: EXPERIMENTAL
Intervention: Oral and dental education in one session for children and parents
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group (no instructions)
Number of subjects: 160
Study: 19936370

Group type: EXPERIMENTAL
Intervention: OptiNose's novel delivery device (Opt‐FP) 400 microg twice daily for 12 weeks
Number of subjects: 109
Study: 17956212

Group type: EXPERIMENTAL
Intervention: Diclod (diclofenac sodium)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Rinderon (betamethasone phosphate)
Number of subjects: 63
Study: 13680266

Group type: EXPERIMENTAL
Intervention: recombinant follicle‐stimulating hormone (rFSH) + human menopausal gonadotrophin (HMG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: recombinant follicle‐stimulating hormone (rFSH) alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: short protocol with luteinizing hormone (LH) added from the beginning
Number of subjects: 0

Group type: COMPARATOR
Intervention: high day 3 serum FSH concentrations (>9 mIU/ml)
Number of subjects: 0
Study: 11273950

Group type: EXPERIMENTAL
Intervention: Ketoprofen (100 mg IV during surgery and 8 hours later)
Number of subjects: 214

Group type: COMPARATOR
Intervention: Control (propacetamol alone)
Number of subjects: 214
Study: 9228494

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) patch therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (normotensive patients)
Number of subjects: 0
Study: 8427034

Group type: EXPERIMENTAL
Intervention: Influenza subunit vaccine (0, 10, 20, and 60 micrograms)
Number of subjects: 0
Study: 3036023

Group type: EXPERIMENTAL
Intervention: Nalidixic acid (2%) applied twice daily under occlusion
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Novobiocin (2% or 5%) applied twice daily under occlusion
Number of subjects: 7

Group type: COMPARATOR
Intervention: Methylcellulose alone (control)
Number of subjects: 7
Study: 28295686

Group type: EXPERIMENTAL
Intervention: Sprint Interval Training (SIT)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 26
Study: 27240787

Group type: EXPERIMENTAL
Intervention: Raltegravir group (oral ritonavir-boosted lopinavir 100 mg ritonavir, 400 mg lopinavir plus 400 mg raltegravir twice a day)
Number of subjects: 515

Group type: COMPARATOR
Intervention: NRTI group (ritonavir-boosted lopinavir plus two or three NRTIs)
Number of subjects: 515

Group type: EXPERIMENTAL
Intervention: Raltegravir group
Number of subjects: 515

Group type: COMPARATOR
Intervention: NRTI group
Number of subjects: 515

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 515
Study: 24912498

Group type: EXPERIMENTAL
Intervention: MVA85A
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (Candin)
Number of subjects: 0
Study: 23252844

Group type: EXPERIMENTAL
Intervention: ICF-based patient education programme
Number of subjects: 213

Group type: COMPARATOR
Intervention: Attention-placebo control intervention
Number of subjects: 213
Study: 21651955

Group type: EXPERIMENTAL
Intervention: 3% TiO(2) nanoparticles
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5% TiO(2) nanoparticles
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 7% TiO(2) nanoparticles
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TiO(2) nanoparticles (3%, 5%, 7%)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unmodified GI
Number of subjects: 0
Study: 18266660

Group type: EXPERIMENTAL
Intervention: Paroxysmal AF
Number of subjects: 7329

Group type: COMPARATOR
Intervention: Persistent AF
Number of subjects: 7329

Group type: EXPERIMENTAL
Intervention: High risk paroxysmal AF (>=2 stroke risk factors)
Number of subjects: 7329

Group type: COMPARATOR
Intervention: High risk persistent AF (>=2 stroke risk factors)
Number of subjects: 7329

Group type: EXPERIMENTAL
Intervention: Elderly paroxysmal AF
Number of subjects: 7329

Group type: COMPARATOR
Intervention: Elderly persistent AF
Number of subjects: 7329

Group type: EXPERIMENTAL
Intervention: Vitamin K antagonist (VKA)‐naive paroxysmal AF
Number of subjects: 7329

Group type: COMPARATOR
Intervention: Previous VKA takers with paroxysmal AF
Number of subjects: 7329
Study: 17064200

Group type: EXPERIMENTAL
Intervention: Pharmacist intervention group
Number of subjects: 463

Group type: COMPARATOR
Intervention: Usual care (control) group
Number of subjects: 463

Group type: COMPARATOR
Intervention: Pharmacist intervention group and Usual care (control) group
Number of subjects: 463
Study: 12832367

Group type: EXPERIMENTAL
Intervention: Oxytocin antagonist (atosiban)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 10
Study: 11167965

Group type: EXPERIMENTAL
Intervention: Exorex (1% coal tar with esterified essential fatty acids)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Coal tar control (Exorex without the essential fatty acid component)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Exorex and Coal tar control
Number of subjects: 20
Study: 9327820

Group type: EXPERIMENTAL
Intervention: Functional Reach Test (FRT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Postural sway measures on the Balance System
Number of subjects: 20
Study: 8447842

Group type: EXPERIMENTAL
Intervention: Intramuscular administration of 2 mg folic acid
Number of subjects: 15

Group type: COMPARATOR
Intervention: Intravenous administration of 2 mg folic acid
Number of subjects: 15
Study: 2447860

Group type: EXPERIMENTAL
Intervention: Peripheral intravenous crystalloid solution and routine ward observations
Number of subjects: 100

Group type: COMPARATOR
Intervention: Peritoneal lavage as adjunctive therapy
Number of subjects: 100
Study: 29710380

Group type: EXPERIMENTAL
Intervention: TNA + multivitamin (Group A)
Number of subjects: 30

Group type: COMPARATOR
Intervention: TNA + normal saline (Group B)
Number of subjects: 30
Study: 27833922

Group type: EXPERIMENTAL
Intervention: Lay Health Trainer (LHT) intervention
Number of subjects: 76

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 76
Study: 24002913

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 100 mg
Number of subjects: 213

Group type: COMPARATOR
Intervention: Control (no antiplatelet agents)
Number of subjects: 213
Study: 23189232

Group type: EXPERIMENTAL
Intervention: Soy milk
Number of subjects: 24

Group type: COMPARATOR
Intervention: Cow's milk
Number of subjects: 24
Study: 15881644

Group type: EXPERIMENTAL
Intervention: Complex therapy (CT) plus a composition of replaceable amino acids (CRAA) sublingually and orally
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Complex therapy (CT) plus melatonin in doses of 3 and 6 mg
Number of subjects: 129

Group type: COMPARATOR
Intervention: Complex therapy (CT) only
Number of subjects: 129

Group type: COMPARATOR
Intervention: Complex therapy (CT) plus placebo
Number of subjects: 129
Study: 12882479

Group type: EXPERIMENTAL
Intervention: Physical activity (150 min weekly of moderate intensity physical activity, such as brisk walking)
Number of subjects: 0
Study: 9779029

Group type: EXPERIMENTAL
Intervention: Enoxaparin (lower dose 1.0 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8681499

Group type: EXPERIMENTAL
Intervention: Tolrestat 200 mg orally once daily for six months
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 2796443

Group type: EXPERIMENTAL
Intervention: mecillinam (1.200 mg/day p.o.) for 5 days
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: co‐trimoxazole (1.600 mg/day p.o.) for 5 days
Number of subjects: 134

Group type: COMPARATOR
Intervention: diet only
Number of subjects: 134
Study: 682818

Group type: EXPERIMENTAL
Intervention: Subcutaneous lateral sphincterotomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Digital dilatation and sphincterotomy
Number of subjects: 0
Study: 29461134

Group type: EXPERIMENTAL
Intervention: Self-reported methamphetamine use in the past 3 days
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Self-reported methamphetamine use over an extended recall period of 1 month
Number of subjects: 90
Study: 27130038

Group type: EXPERIMENTAL
Intervention: Facial botulinum Toxin‐A (BTX) injections
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 25002389

Group type: EXPERIMENTAL
Intervention: Normothermic ex vivo allograft blood perfusion using an organ care system (OCS)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Cold static storage with histidine-tryptophan-ketoglutarate solution (Custodiol)
Number of subjects: 159
Study: 22190554

Group type: EXPERIMENTAL
Intervention: Didactic plus simulation-based training
Number of subjects: 54

Group type: COMPARATOR
Intervention: Didactic training alone
Number of subjects: 54
Study: 20568303

Group type: EXPERIMENTAL
Intervention: peginterferon (PEG‐IFN) alfa‐2b at 1.5 microg/kg/week with ribavirin (RBV) at 800 to 1400 mg/day
Number of subjects: 3070

Group type: EXPERIMENTAL
Intervention: peginterferon (PEG‐IFN) alfa‐2b at 1.0 microg/kg/week with RBV at 800 to 1400 mg/day
Number of subjects: 3070

Group type: EXPERIMENTAL
Intervention: peginterferon (PEG‐IFN) alfa‐2a at 180 microg/week with RBV at 1000 to 1200 mg/day
Number of subjects: 3070

Group type: EXPERIMENTAL
Intervention: Statin pretreatment
Number of subjects: 3070

Group type: COMPARATOR
Intervention: No statin pretreatment
Number of subjects: 3070

Group type: COMPARATOR
Intervention: Normal LDL and HDL levels
Number of subjects: 3070
Study: 18502512

Group type: EXPERIMENTAL
Intervention: Laser treatment
Number of subjects: 1052

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 1052
Study: 16105990

Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stents
Number of subjects: 250

Group type: COMPARATOR
Intervention: Sirolimus-eluting stents
Number of subjects: 250
Study: 11832869

Group type: EXPERIMENTAL
Intervention: Snowshoe training
Number of subjects: 17

Group type: COMPARATOR
Intervention: Running training
Number of subjects: 17
Study: 10081520

Group type: EXPERIMENTAL
Intervention: Folic acid 5 mg daily
Number of subjects: 29

Group type: COMPARATOR
Intervention: Folic acid 1 mg daily
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Betaine 4 g daily
Number of subjects: 29
Study: 7751897

Group type: EXPERIMENTAL
Intervention: Cisplatin (CDDP) 100 mg/m2 intravenously on day 1 and Fluorouracil (FU) 5,000 mg/m2 over a 120-hour continuous infusion
Number of subjects: 95

Group type: COMPARATOR
Intervention: Carboplatin (CBDCA) 400 mg/m2 over a 24-hour continuous infusion on day 1 and Fluorouracil (FU) with the same schedule
Number of subjects: 95
Study: 2309606

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 30781908

Group type: EXPERIMENTAL
Intervention: Intra-Uterine Contraceptive Devices (IUCD)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (without IUCD)
Number of subjects: 40
Study: 31992269

Group type: EXPERIMENTAL
Intervention: Self-Compassion Online (SCO) program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 0
Study: 31133629

Group type: EXPERIMENTAL
Intervention: Neck pain
Number of subjects: 1221

Group type: EXPERIMENTAL
Intervention: Shoulders pain
Number of subjects: 1221

Group type: EXPERIMENTAL
Intervention: Low back pain
Number of subjects: 1221

Group type: EXPERIMENTAL
Intervention: Drug consumption for MSP
Number of subjects: 1221

Group type: EXPERIMENTAL
Intervention: Sleep disturbance
Number of subjects: 1221

Group type: EXPERIMENTAL
Intervention: Aggressive behaviors
Number of subjects: 1221
Study: 28219458

Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy - Cognitive Only (CPT)
Number of subjects: 8
Study: 25755212

Group type: EXPERIMENTAL
Intervention: ivacaftor
Number of subjects: 209

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 209
Study: 23122918

Group type: EXPERIMENTAL
Intervention: Anodal tDCS of the somatosensory cortex for 5 consecutive days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 0
Study: 21059664

Group type: EXPERIMENTAL
Intervention: Modified Nottingham Extended ADL Scale
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Frenchay Activities Index
Number of subjects: 70
Study: 18836986

Group type: EXPERIMENTAL
Intervention: Increasing thickness of carotid artery intima-media thickness (CIMT)
Number of subjects: 504

Group type: COMPARATOR
Intervention: Coronary artery calcium (CAC)
Number of subjects: 504

Group type: COMPARATOR
Intervention: Abdominal aortic calcium (AAC)
Number of subjects: 504
Study: 17292362

Group type: EXPERIMENTAL
Intervention: Single blastocyst transfer (SBT) on day 5
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single embryo transfer (SET) on day 3
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single blastocyst transfer (SBT) after excellent-quality embryos became available
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single embryo transfer (SET) after excellent-quality embryos became available
Number of subjects: 0
Study: 15565613

Group type: EXPERIMENTAL
Intervention: Epoetin alfa (40,000 units subcutaneously weekly)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Epoetin alfa
Number of subjects: 185
Study: 12171679

Group type: EXPERIMENTAL
Intervention: SPF 15 sunscreen containing 0.25% AGR (Eucerin Gel Cream Phase 2) applied 30 minutes before UVA irradiation.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: SPF 15 sunscreen containing 0.25% AGR (Eucerin Gel Cream Phase 2) with additional pretreatment using AGR-containing vehicle (Eucerin Gel Cream Phase 1) twice daily for 3 and 7 days.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Pre-sun preparation applied twice daily for 1 week before vacation and SPF 15 sunscreen used 30 minutes before sun exposure.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Treatment for acne aestivalis patients.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Untreated control area during UVA irradiation.
Number of subjects: 30
Study: 9762797

Group type: EXPERIMENTAL
Intervention: Eucapnic COPD patients
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Hypercapnic COPD patients
Number of subjects: 53

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Eucapnic vs Hypercapnic COPD
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Logistic regression analysis
Number of subjects: 53
Study: 7848005

Group type: EXPERIMENTAL
Intervention: Azithromycin (500 mg daily for 10 days)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Azithromycin (500 mg every two days)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Erythromycin (30 g)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Penicillin (300,000 U every 3 hours for 16‐28 days)
Number of subjects: 100
Study: 3288075

Group type: EXPERIMENTAL
Intervention: Elevated intranasal temperature (inhalation of saturated hot air at 42-44 degrees C)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 78
Study: 30426269

Group type: EXPERIMENTAL
Intervention: Collarless straight tapered stem (Corail®)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Contact points of the implant with femoral cortical bone
Number of subjects: 40
Study: 27545871

Group type: COMPARATOR
Intervention: 25% SLS formulation
Number of subjects: 49

Group type: COMPARATOR
Intervention: 12.5% SLS formulation
Number of subjects: 49

Group type: COMPARATOR
Intervention: 3% SLS formulation
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Reference 50% SLS formulation
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Alectinib (600 mg)
Number of subjects: 49
Study: 24382130

Group type: EXPERIMENTAL
Intervention: Behavioural Activation (BA) online training
Number of subjects: 540
Study: 24283276

Group type: EXPERIMENTAL
Intervention: High-fiber formula (FF)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: High-monounsaturated fatty acid formula (MF)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control formula (CF)
Number of subjects: 8
Study: 20836913

Group type: EXPERIMENTAL
Intervention: Annual medication assessment as part of a Comprehensive Geriatric Assessment (CGA) by physicians (n = 361)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Control group (n = 339)
Number of subjects: 1000
Study: 18323492

Group type: EXPERIMENTAL
Intervention: Constraint‐induced movement therapy
Number of subjects: 36

Group type: COMPARATOR
Intervention: Comparison therapy
Number of subjects: 36
Study: 17009827

Group type: EXPERIMENTAL
Intervention: Gibson-Piggott procedure
Number of subjects: 37
Study: 14619087

Group type: EXPERIMENTAL
Intervention: Mandatory subhepatic drainage (324 patients)
Number of subjects: 689

Group type: COMPARATOR
Intervention: Indicated subhepatic drainage (365 patients)
Number of subjects: 689
Study: 10973767

Group type: EXPERIMENTAL
Intervention: Eptifibatide (180 microg/kg bolus followed by continuous infusion of 0.75 microg/kg/min for 72 hours)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Eptifibatide (combined groups)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Eptifibatide
Number of subjects: 181
Study: 8856800

Group type: EXPERIMENTAL
Intervention: Assessment of history for apnea or respiratory failure
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Assessment of reason for hospitalization
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Assessment of cyanosis
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Assessment of respiratory rate
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Assessment of retractions
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Assessment of oxygen saturation measures
Number of subjects: 137
Study: 1501118

Group type: EXPERIMENTAL
Intervention: Diphenhydramine (100, 200 and 400 mg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Lorazepam (1 and 4 mg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Methocarbamol (2.25 and 9 g)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 6440982

Group type: EXPERIMENTAL
Intervention: Auranofin (AF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30850411

Group type: EXPERIMENTAL
Intervention: Ulinastatin (intravenously administered every 8 hours for a total of 600,000 U/day for five consecutive days)
Number of subjects: 880

Group type: COMPARATOR
Intervention: Control group (treatment-as-usual)
Number of subjects: 880
Study: 29174695

Group type: EXPERIMENTAL
Intervention: Inactivated oral cholera vaccine (OCV)
Number of subjects: 59635

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59635
Study: 26968693

Group type: EXPERIMENTAL
Intervention: Fast-track program (FT)
Number of subjects: 258

Group type: COMPARATOR
Intervention: Standard program
Number of subjects: 258
Study: 25076161

Group type: EXPERIMENTAL
Intervention: Rifaximin 550 mg twice daily for 2 days before PET/CT scan
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no antibiotics)
Number of subjects: 30
Study: 22851598

Group type: EXPERIMENTAL
Intervention: Insulin detemir (IDet)
Number of subjects: 310

Group type: COMPARATOR
Intervention: Neutral protamine Hagedorn (NPH)
Number of subjects: 310